ACHN Achillion Pharmaceuticals, Inc.

4.07
+0.01  (0.25%)
Previous Close 4.06
Open 4.06
Price To book 1.38
Market Cap 556.29M
Shares 136,680,000
Volume 1,286,282
Short Ratio 5.71
Av. Daily Volume 2,170,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data released November 2016. Phase 2 planned.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2b trial initiation announced November 30, 2016.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)

Latest News

  1. J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
  2. Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : January 11, 2017
  3. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : January 10, 2017
  4. Where are the opportunities for investors in health care?
  5. Achillion Receives $15M from J&J for HCV Study Enrolment
  6. ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
  7. Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
  8. Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
  9. These 5 Stocks Under $10 Could Make You a Lot of Money
  10. Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
  11. The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November
  12. Has The Smart Money Found A Winner in Infoblox Inc (BLOX)?
  13. Achillion, J&J to Initiate Phase IIb Study on HCV Combo
  14. Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
  15. Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
  16. This Metric Says It May Be Time to Buy Achillion Pharmaceuticals, Inc. (ACHN)
  17. Achillion Pharmaceuticals (ACHN) is Oversold: Can It Recover?
  18. Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone
  19. Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) to Ring The Nasdaq Stock Market Closing Bell
  20. ACHILLION PHARMACEUTICALS INC Financials

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536715
  2. 8-K - Current report 162071385
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161986764
  4. 8-K - Current report 161971911
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971848
  6. 8-K - Current report 161807602
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807583
  8. 8-K - Current report 161682405
  9. 8-K - Current report 161615674
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161615592